All current hantavirus vaccine candidates remain in preclinical or early phase 1 stages, with no products advancing to pivotal efficacy trials or regulatory review that could enable licensure by the end of 2026. mRNA platforms from Moderna and UTMB, plus DNA and viral-vectored constructs, have shown strong immunogenicity and single-dose protection in rodent models against strains like Andes virus, yet none have completed human safety or dosing studies at scale. Regulatory pathways require extensive phase 2/3 data, which are hindered by the disease’s low incidence and geographic variability. Recent outbreaks have spurred funding interest, but timelines for manufacturing scale-up and approval exceed the remaining months. Only an unforeseen emergency-use authorization tied to a major epidemic could alter this trajectory before year-end.